Table 2.
Patient Characteristics according to WHO 2016 classification
| WHO 2016 Subtype | Patients n (%) | WBC (G/L) median (range) | Hb (g/dL) median (range) | Plt (G/L) median (range) | Ferritin (µg/L) median (range) | LDH (U/L) median (range) |
|---|---|---|---|---|---|---|
| MDS-5q | 10 (5.9) | 4.84 (2.32-8.26) | 9.15 (7.7-11.2) | 317 (114-898) | 371.5 (42-1390) | 178.5 (158-283) |
| MDS-EB-1 | 29 (17.2) | 3.26 (0.63-76.5) | 9.7 (6.8-13.6) | 90 (13-398) | 263 (36-1170) | 245 (147-1059) |
| MDS-EB-2 | 28 (16.6) | 2.69 (0.58-32) | 8.75 (7.1-12.6) | 93 (16-390) | 294 (10-1980) | 225 (144-2600) |
| MDS-SLD | 18 (10.7) | 4.12 (1.79-10.2) | 10.2 (5.6-12.2) | 144 (3-648) | 237.5 (96-902) | 227.5 (137-369) |
| MDS-RS-SLD | 26 (15.4) | 5.05 (1.66-12.11) | 9.5 (6.7-11) | 236 (31-369) | 453 (23-7415) | 180 (121-1751) |
| MDS-MLD | 26 (15.4) | 3.08 (1.7-6.8) | 9.7 (7.3-13.3) | 89 (6-295) | 538 (43-2300) | 203.5 (127-641) |
| MDS-RS-MLD | 12 (7.1) | 4.47 (1.19-6.8) | 9.3 (5.9-11.4) | 133 (64-807) | 695 (325-5450) | 162 (103-226) |
| CMML-1 | 10 (5.9) | 7.89 (2.83-18.89) | 10.5 (6.7-14.2) | 96 (3-241) | 488.5 (64-1100) | 179 (137-862) |
| CMML-2 | 2 (1.1) | 16.52 (6.4-26.64) | 8.4 (5.4-11.4) | 75 (71-80) | 1125.5 (71-2180) | 335 (301-369) |
| AML dys. | 7 (4.1) | 2.99 (1.14-24.37) | 10.1 (7.5-11.4) | 50 (28-241) | 879 (339-1250) | 264 (117-395) |
Abbreviations: WHO, World Health Organization; WBC, white blood count; Hb, hemoglobin; Plt, platelets; LDH; lactate dehydrogenase; MDS, Myelodysplatic Syndrome; MDS 5q-, MDS with isolated 5q-; MDS-EB1, MDS with excess of blasts-1; MDS-EB2, MDS with excess of blasts-2; MDS-SLD, MDS with single-lineage dysplasia; MDS-RS-SLD, MDS with ring sideroblasts (RS) and single-lineage dysplasia; MDS-MLD, MDS with multilineage dysplasia; MDS-RS-MLD, MDS with RS and multilineage dysplasia; CMML, Chronic Myelomonocytic Leukemia; AML dys., Acute Myeloid Leukemia with myelodysplasia-related changes.